Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Genomic Health, Inc.    GHDX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
29.59(c) 29.37(c) 29(c) 29.49(c) 30.61(c) Last
93 379 100 166 107 776 109 024 263 861 Volume
+0.24% -0.74% -1.26% +1.69% +3.80% Change
More quotes
Financials ($)
Sales 2017 356 M
EBIT 2017 -1,18 M
Net income 2017 0,22 M
Finance 2017 65,7 M
Yield 2017 -
Sales 2018 392 M
EBIT 2018 13,0 M
Net income 2018 10,6 M
Finance 2018 84,5 M
Yield 2018 -
P/E ratio 2017 1 749,14
P/E ratio 2018 93,69
EV / Sales2017 2,77x
EV / Sales2018 2,46x
Capitalization 1 051 M
More Financials
Company
Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions.Its uses a platform which translates a massive... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMIC HEALTH, INC.
05/25 GENOMIC HEALTH : Prospective Oncotype DX® Genomic Prostate Score Test Data Prese..
05/25 GENOMIC HEALTH : Oncotype DX® Genomic Prostate Score GPS Test Predicts 10-year R..
05/25 GENOMIC HEALTH : to Present at Jefferies 2017 Healthcare Conference
05/19 GENOMIC HEALTH,INC. (NASDAQ : GHDX) Files An 8-K Entry into a Material Definitiv..
05/19 GENOMIC HEALTH INC : Entry into a Material Definitive Agreement, Financial State..
05/13 GENOMIC HEALTH : Prospective Oncotype DX® Genomic Prostate Score™ Test Dat..
05/12 GENOMIC HEALTH : Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts ..
05/11 GENOMIC HEALTH : Announces Favorable Draft Local Coverage Determination LCD on M..
05/10 GENOMIC HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
05/10 GENOMIC HEALTH : to Present at Bank of America Merrill Lynch 2017 Health Care Co..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/25Fred E. Cohen Sells 8,250 Shares of Genomic Health, Inc. $GHDX Stock  
05/25Genomic Health, Inc. $GHDX Director Sells $493,020.00 in Stock  
05/25Genomic Health to Present at Jefferies 2017 Healthcare Conference  
05/25Genomic Health : to Present at Jefferies 2017 Healthcare Conference  
05/24Genomic Health, Inc. $GHDX Director Sells $243,705.00 in Stock  
More tweets
Qtime:16
News from SeekingAlpha
05/13 Genomic Health's (GHDX) CEO Kim Popovits on Q1 2017 Results - Earnings Call T..
05/09 Genomic Health beats by $0.05, misses on revenue
05/08 Notable earnings after Tuesday?s close
05/05 Genomic Health updates on Oncotype DX Genomic Prostate Score
04/06 FDA OKs direct-to-consumer genetic tests
Advertisement
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Full-screen chart
Technical analysis trends GENOMIC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 31,6 $
Spread / Average Target 3,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kimberly J. Popovits Chairman, President & Chief Executive Officer
G. Bradley Cole COO, CFO & Principal Accounting Officer
Steven Shak Chief Scientific Officer
Phillip G. Febbo Chief Medical Officer
Michael Vedda Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GENOMIC HEALTH, INC.4.15%1 051
INCYTE CORPORATION34.02%27 518
QUINTILES IMS HOLDINGS..13.11%18 872
LONZA GROUP AG25.78%15 703
CELLTRION, INC.--.--%10 293
SEATTLE GENETICS, INC.24.26%9 358
More Results